v
Search
Advanced Search

Publications > Journals > Journal of Clinical and Translational Hepatology > Article Full Text

  • Original Article
  • OPEN ACCESS

Risk of Coronary Artery Disease in Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis

  • Chunru Gu1,#,
  • Liyan Dong1,#,
  • Lu Chai1,2,#,
  • Zhenhua Tong3,
  • Fangbo Gao1,2,
  • Walter Ageno4,
  • 
Fernando Gomes Romeiro5 and
  • Xingshun Qi1,2,* 
 Author information  Cite
Journal of Clinical and Translational Hepatology   2024

doi: 10.14218/JCTH.2024.00226

Abstract

Background and Aims

Coronary artery disease (CAD) is increasingly observed in patients with liver cirrhosis. However, data on the incidence and prevalence of CAD in cirrhotic patients are heterogeneous, and the association remains uncertain. In this study, we aimed to conduct a systematic review and meta-analysis to address these issues.

Methods

PubMed, EMBASE, and Cochrane Library databases were searched. Incidence, prevalence, and factors associated with CAD were pooled using a random-effects model. Risk ratio (RR) and odds ratio (OR), with their 95% confidence interval (CI), were calculated to evaluate differences in CAD incidence and prevalence between patients with and without liver cirrhosis.

Results

Fifty-one studies were included. The pooled incidences of CAD, acute coronary syndromes, and myocardial infarction (MI) were 2.28%, 2.02%, and 1.80%, respectively. Liver cirrhosis was not significantly associated with CAD incidence (RR = 0.77; 95% CI = 0.46–1.28) or MI (RR = 0.87; 95% CI = 0.49–1.57). The pooled prevalence of CAD, acute coronary syndromes, and MI was 18.87%, 12.54%, and 6.12%, respectively. Liver cirrhosis was not significantly associated with CAD prevalence (OR = 1.29; 95% CI = 0.83–2.01) or MI (OR = 0.58; 95% CI = 0.28–1.22). Non-alcoholic steatohepatitis, hepatitis C virus, advanced age, male sex, diabetes mellitus, hypertension, hyperlipidemia, smoking history, and family history of CAD were significantly associated with CAD in cirrhotic patients.

Conclusions

CAD is common in cirrhotic patients, but cirrhosis itself may not be associated with an increased CAD risk. In addition to traditional risk factors, non-alcoholic steatohepatitis and hepatitis C virus infection are also associated with CAD presence in cirrhotic patients.

Graphical Abstract

Keywords

Coronary artery disease, Acute coronary syndromes, Myocardial infarction, Liver cirrhosis, Epidemiology, Association, Meta-analysis

Introduction

Coronary artery disease (CAD) and liver cirrhosis are major causes of death worldwide and share common risk factors, such as obesity, diabetes, and metabolic syndrome.1,2 CAD is classified into chronic coronary syndromes and acute coronary syndromes (ACS).2 In 2020, an estimated 244.11 million people globally lived with CAD, and 8.95 million patients died from it, especially from ACS.3 Liver cirrhosis is the end stage of chronic liver disease and leads to lethal complications, including bacterial infection, acute kidney injury, and acute gastrointestinal bleeding.1 In 2017, it was reported that 122.60 million people worldwide lived with liver cirrhosis, with 1.32 million deaths attributed to the disease.4

Liver cirrhosis is often complicated by systemic inflammation, hyperactivity of the sympathetic nervous system, and increased cardiac output, all of which are potentially associated with the development of CAD.5,6 Additionally, patients with liver cirrhosis have a high risk of bleeding due to the coexistence of portal hypertension and thrombocytopenia.1 Consequently, CAD patients with liver cirrhosis are less likely to receive antithrombotic drugs and have a higher risk of adverse outcomes, including mortality, readmission, and gastrointestinal bleeding,7 compared to those without liver cirrhosis. Conversely, the presence of CAD also increases post-transplant mortality in patients with advanced liver cirrhosis.8

Epidemiological data on CAD in patients with cirrhosis are heterogeneous among studies,9,10 probably due to differences in target populations and the definitions and diagnostic approaches of CAD. To the best of our knowledge, only one meta-analysis has investigated the prevalence of CAD in liver cirrhosis, finding a pooled prevalence of 12.6%, though it included only five studies.10 In recent years, the number of studies addressing the epidemiology of CAD in patients with cirrhosis has rapidly increased. However, there remains a lack of studies to estimate the incidence and prevalence of CAD in patients with cirrhosis, assess the association between the two diseases, and identify factors associated with CAD in cirrhosis. Therefore, we conducted this systematic review and meta-analysis to address these gaps.

Methods

This systematic review and meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) and Meta-analysis of Observational Studies in Epidemiology guidelines.11,12

Registration

This study was registered in the International Prospective Register of Systematic Reviews (hereinafter referred to as PROSPERO) with the registration number CRD42022315248. There was no significant deviation from the protocol registered in PROSPERO.

Search strategy

We searched the PubMed, EMBASE, and Cochrane Library databases from inception to May 17, 2023, without language restriction. Reference lists from relevant papers were manually screened to identify eligible studies. The search terms were as follows: ((liver cirrhosis [all fields]) OR (hepatic cirrhosis [all fields])) AND ((coronary disease [all fields]) OR (coronary heart disease [all fields]) OR (coronary artery disease [all fields]) OR (coronary arteriosclerosis [all fields]) OR (myocardial infarction [all fields]) OR (acute coronary syndrome [all fields]) OR (angina [all fields])).

Selection criteria

Selection criteria were established according to the PICO rule. Participants should be cirrhotic patients, regardless of stages and etiologies. Intervention was not restricted. Comparison should be conducted between patients with and without cirrhosis, if any. The outcome should be the incidence and/or prevalence of CAD.

Exclusion criteria were as follows: 1) duplicated articles; 2) comments, notes, or letters; 3) guidelines or consensus statements; 4) reviews and/or meta-analyses; 5) case reports; 6) experimental or animal studies; 7) patients not diagnosed with liver cirrhosis; 8) CAD not evaluated; 9) overlapping relevant data among studies; and 10) relevant data that could not be extracted.

Definitions

CAD, which refers to the development of thrombosis in the coronary vessels, is divided into chronic coronary syndrome and ACS. ACS primarily includes unstable angina, non-ST-segment elevation myocardial infarction (hereinafter referred to as NSTEMI), and ST-segment elevation myocardial infarction (hereinafter referred to as STEMI). NSTEMI and STEMI are collectively defined as myocardial infarction (MI). The incidence of CAD refers to the new onset of CAD events after a diagnosis of cirrhosis based on data from cohort studies. The prevalence of CAD refers to the presence of CAD in cirrhosis based on data from cross-sectional studies. Severity of CAD was categorized as non-obstructive, obstructive, and severe CAD, defined as luminal stenosis of <50%, ≥50%, and ≥70% in one of the three major coronary arteries, respectively.13

Data extraction

Two authors (CG and LD) independently extracted and evaluated the following data from the included studies: first author, publication year, region, enrollment period, study design, type of publication, number of patients with and without liver cirrhosis, number of patients who developed CAD, endpoint events (i.e., CAD, ACS, and MI), and etiology of cirrhosis. To evaluate the differences in baseline characteristics between cirrhotic patients with and without CAD, the following data were further extracted: diabetes mellitus, hypertension, hyperlipidemia, smoking history, family history of CAD, hepatocellular carcinoma, body mass index, and Child-Pugh and Model for End-Stage Liver Disease (MELD) scores. Disagreements between the two authors (CG and LD) were resolved through discussion with a third author (XQ) until a consensus was achieved.

Study quality assessment

Included studies were assessed using the Joanna Briggs Institute Critical Evaluation.14 Assessment was mainly based on the risk of bias, adequate reporting, and statistical analysis. Responses included “yes”, “no”, “unclear”, and “not applicable”. Only “yes” was scored as one, while “no”, “unclear”, or “not applicable” were scored as zero. The maximum score was 10. Studies that scored ≥7, 5–6, and ≤4 were classified as high, moderate, and low quality, respectively.

Statistical analyses

All analyses were conducted using RStudio version 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS Version 20.0 (SPSS Software, Chicago, IL, USA). The incidence, prevalence, and risk factors of CAD were pooled using a random-effects model. The pooled incidence and prevalence of CAD were expressed as percentages with their 95% confidence intervals (CIs). The incidence rate of CAD in cirrhotic patients was calculated by dividing the number of individuals with new-onset CAD by the total number of individuals with liver cirrhosis. The incidence rate per 1,000 person-years was also calculated, when applicable. The prevalence rate of CAD in cirrhotic patients was calculated by dividing the total number of individuals with CAD by the total number of individuals with liver cirrhosis. Odds ratios (ORs), risk ratios (RRs), and mean differences (MD) with their 95% CIs were calculated for the combined estimates of raw data, when appropriate. A p-value of <0.05 was considered statistically significant. When the reported outcome was incomplete for meta-analysis, results were described in narrative form. Statistical heterogeneity was assessed via I2 statistics and the Chi2 test, where I2 values of 25%, 50%, and 75% represented low, moderate, and high degrees of heterogeneity, respectively, and p < 0.10 by the Chi2 test was considered significant for heterogeneity. The Egger test was used to assess publication bias, with p < 0.1 indicating significant publication bias. Meta-regression and subgroup analyses were performed to explore the sources of heterogeneity. The following covariates were used in the meta-regression and subgroup analyses: region (America vs. Asia vs. Europe vs. Africa), publication year (Before 2015 vs. After 2015), study design (Prospective vs. Retrospective), type of publication (Full-texts vs. Abstracts), study quality (High and Moderate vs. Low), sample size (≥4,545 vs. <4,545; ≥243 vs. <243), etiology of liver cirrhosis (Non-alcoholic steatohepatitis [NASH] cirrhosis vs. Hepatitis C virus [HCV] cirrhosis vs. Alcoholic cirrhosis vs. Primary biliary cirrhosis [PBC] vs. Hepatitis B virus [HBV] cirrhosis), sex (Male vs. Female), mean age (≥57 years vs. <57 years; ≥56 years vs. <56 years), diabetes mellitus (Yes vs. No), hypertension (Yes vs. No), smoking history (Yes vs. No), hyperlipidemia (Yes vs. No), family history of CAD (Yes vs. No), and severity of CAD (Non-obstructive vs. Obstructive vs. Severe). The interaction between subgroups was tested, with p < 0.1 considered indicative of a statistically significant interaction.

Results

Study selection

Initially, 4,149 papers were identified. Ultimately, 51 studies were included (Fig. 1). Of these, 12 studies reported the incidence of CAD in patients with liver cirrhosis,15–26 and 39 studies reported the prevalence of CAD.9,27–64 The quality assessment is provided in Supplementary Table 1.

Flow chart of study selection.
Fig. 1  Flow chart of study selection.

CAD, coronary artery disease.

Table 1

Characteristics of studies regarding the incidence of CAD in liver cirrhosis

First author (Year)RegionStudy designPublished formEnrollment periodTarget populationType of CADNo. of cases (CAD/total)No. of controls (CAD/total)
Huang (2023)15USARetro-cohortFull-text2018–2019CirrhosisMI451/26,37410,046/1,271,645
Abdul-Rahman (2022)16GermanPro-cohortAbstract2010–2019CirrhosisMI182/6,51733,371/1,283,483
Jepsen (2021)17DenmarkPro-cohortFull-text1996–2019CirrhosisMI56/5,854416/23,870
Deleuran (2020)18DenmarkPro-cohortFull-text1996–2014Alcoholic cirrhosisMI281/22,8673,267/107,485
Cacoub (2018)21FrancePro-cohortFull-text2006–2015HCV cirrhosisCAD10/878NA
MI8/878
Lin (2018)20ChinaRetro-cohortFull-text2000–2010CirrhosisACS1,157/57,2141,102/57,214
Tsai (2018)19ChinaRetro-cohortFull-text2004–2011CirrhosisCAD165/3,2362,814/16,180
Serper (2017)22USAPro-cohortAbstract2008–2010CirrhosisMI923/21,984NA
Wang (2014)23ChinaRetro-cohortFull-text2007–2013PBCCAD41/2,675NA
Pavel (2012)24SpainPro-cohortAbstractNACirrhosisACS6/277NA/612
Solaymani-Dodaran (2008)25UKRetro-cohortFull-textNAPBCMI22/930222/9,202
Longo (2002)26ItalyPro-cohortFull-text1974–1997PBCCAD8/350NA

ACS, acute coronary syndromes; CAD, coronary artery disease; HCV, hepatitis C virus; MI, myocardial infarction; PBC, primary biliary cirrhosis; Pro, prospective; Retro, retrospective; UK, United Kingdom of Great Britain and Northern Ireland; USA, United States of America.

Incidence of CAD in liver cirrhosis

Characteristics

Characteristics of the included studies that reported the incidence of CAD are shown in Table 1.15-26 Among the 12 studies, two studies reported the incidence of ACS,20,24 and seven reported MI15–18,21,22,25; four studies provided data to calculate the incidence rate per 1,000 person-years17,18,20,25; two studies were conducted in America,15,22 three in Asia,19,20,23 and seven in Europe16–18,21,24–26; four studies were published before 2015,23–26 and eight after 201515–22; seven studies were prospective cohort studies,16–18,21,22,24,26 and five were retrospective cohort studies15,19,20,23,25; nine studies were published as full-texts,15,17–21,23,25,26 and three as abstracts16,22,24; eight studies were of high or moderate quality,15,17–21,25,26 and four were of low quality.16,22–24

CAD

Based on data from the 12 studies,15–26 the pooled incidence of CAD in liver cirrhosis was 2.28% (95% CI = 1.55–3.01%) (Supplementary Fig. 1A). The pooled incidence of CAD was 3.01 (95% CI = 2.05–4.15) per 1,000 person-years. Significant heterogeneity was observed (I2 = 97.9%, p < 0.01), with no evidence of publication bias (p = 0.42). Meta-regression analyses did not identify the source of heterogeneity (Supplementary Table 2). Subgroup analyses showed the pooled incidence of CAD in liver cirrhosis was 2.95% in America, 2.86% in Asia, and 1.75% in Europe; 1.91% in studies published before 2015 and 2.38% in studies published after 2015; 2.52% in prospective cohort studies and 2.11% in retrospective cohort studies; 2.00% in full-text publications and 3.21% in abstracts; 2.07% in high- and moderate-quality studies and 2.73% in low-quality studies; 2.15% in studies with sample sizes of ≥4,545 and 2.44% in studies with sample sizes of <4,545; 3.26% in male patients and 3.18% in female patients; 2.02% in patients with a mean age ≥57 years and 1.28% in those with a mean age <57 years; 5.30% in patients with diabetes mellitus and 2.34% in those without; 4.77% in patients with hypertension and 1.37% in those without; 7.96% in patients with hyperlipidemia and 2.67% in those without; 1.81% in PBC, 1.23% in alcoholic liver cirrhosis, and 1.14% in HCV cirrhosis (Table 2). Statistically significant interaction was observed among subgroups according to age and hyperlipidemia status.

Table 2

Incidence of CAD in liver cirrhosis: Results of subgroup analyses

SubgroupNo. 
studiesPooled incidence 
(95%CI)Heterogeneity
Pinteraction
I2 (%)p-value
Region0.43
  America22.95% (0.51–5.39%)99.6<0.01
  Asia32.86% (0.70–5.02%)97.0<0.01
  Europe71.75% (1.14–2.36%)91.3<0.01
Publication year0.45
  After 201582.38% (1.34–3.42%)98.7<0.01
  Before 201541.91% (1.30–2.53%)1.30.39
Study design0.61
  Pro-cohort72.52% (1.26–3.78%)95.0<0.01
  Retro-cohort52.11% (1.17–3.04%)98.7<0.01
Type of publication0.10
  Full-texts92.00% (1.19–2.82%)95.7<0.01
  Abstracts33.21% (2.04–4.39%)94.5<0.01
Study quality0.39
  High and Moderate82.07% (1.15–2.99%)96.3<0.01
  Low42.73% (1.53–3.93%)97.2<0.01
Sample size0.71
  ≥4,54562.15% (1.20–3.10%)98.9<0.01
  <4,54562.44% (1.24–3.64%)93.2<0.01
Sex0.98
  Male23.26% (0.29–6.22%)94.1<0.01
  Female23.18% (0.00–8.94%)98.3<0.01
Age0.02
  ≥5742.02% (1.91–2.14%)90.9<0.01
  <5711.28% (0.92–1.65%)//
Diabetes mellitus0.33
  Yes25.30% (0.23–10.36%)92.4<0.01
  No22.34% (0.00–5.53%)97.3<0.01
Hypertension0.22
  Yes24.77% (0.04–13.49%)95.7<0.01
  No21.37% (0.49–2.68%)76.2<0.01
Hyperlipidemia0.01
  Yes27.96% (5.98–9.95%)00.68
  No22.67% (0.00–6.27%)98.0<0.01
Etiology of cirrhosis0.14
  PBC31.81% (1.28–2.43%)18.70.29
  Alcohol11.23% (1.09–1.37%)//
  HCV11.14% (0.44–1.84%)//

CAD, coronary artery disease; HCV, hepatitis C virus; PBC, primary biliary cirrhosis; Pro, prospective; Retro, retrospective.

Seven studies compared the incidence of CAD between patients with and without liver cirrhosis.15–20,25 The available evidence showed no significant difference in CAD incidence between patients with and without cirrhosis (RR = 0.77; 95% CI = 0.46–1.28; p = 0.31) (Supplementary Fig. 2A). Significant heterogeneity was observed (I2 = 99.2%; p < 0.01), with no evidence of publication bias (p = 0.41).

ACS

Based on data from two studies,20,24 the pooled incidence of ACS in liver cirrhosis was 2.02% (95% CI = 1.91–2.14%) (Supplementary Fig. 1B). No significant heterogeneity was observed (I2 = 0, p = 0.87).

Only one study compared the incidence of ACS between patients with and without liver cirrhosis.20 A competing risk survival analysis using the Fine and Gray proportional subdistribution hazards model showed that ACS incidence was significantly higher in patients with cirrhosis than in those without [subhazard ratio = 1.14; 95% CI = 1.05–1.23; p < 0.01].

MI

Based on data from seven studies,15–18,21,22,25 the pooled incidence of MI in liver cirrhosis was 1.80% (95% CI = 1.18–2.75%) (Supplementary Fig. 1C). Significant heterogeneity was observed (I2 = 98.9%, p < 0.01), with no evidence of publication bias (p = 0.25).

Five studies compared the incidence of MI between patients with and without liver cirrhosis.15–18,25 The available evidence showed no significant difference in MI incidence between patients with and without cirrhosis (RR = 0.87; 95% CI = 0.49–1.57; p = 0.65) (Supplementary Fig. 2B). Significant heterogeneity was observed (I2 = 99.2%; p < 0.01), with no evidence of publication bias (p = 0.57).

Prevalence of CAD in liver cirrhosis

Characteristics

Characteristics of the studies included that reported the prevalence of CAD are shown in Table 3.9,22,27-64 Among the 39 studies, one reported the prevalence of ACS,53 and nine reported MI.28,40,46,51,58,60,62–64 By region, 23 studies were conducted in America,27,29–31,33–35,37,38,40,41,44,47,49–52,54,55,59,62–64 eight in Asia,9,28,39,43,45,53,56,57 six in Europe,42,46,48,58,60,61 and two in Africa.32,36 Regarding publication date, 20 studies were published before 2015,9,46–64 and 19 after 2015.27–45 Thirty-six studies were published as full-texts,9,27–34,36–48,50,51,53–64 and three as abstracts.35,49,52 In terms of quality, 30 studies were of high or moderate quality,9,27–30,33,34,36–47,50,51,53–61 while nine were of low quality.31,32,35,48,49,52,62–64

Table 3

Characteristics of studies regarding the prevalence of CAD in liver cirrhosis

First author (year)RegionPublished formEnrollment periodTarget populationType of CADNo. of cases (CAD/total)No. of controls (CAD/total)
Reznicek (2023)27USAFull-text2013–2018CirrhosisCAD150/693NA
Abureesh (2022)31USAFull-text1999–2019CirrhosisCAD8,210/293,150346,030/55,904,540
Berry (2022)30USAFull-text2011–2020CirrhosisCAD99/1,623NA
Pelayo (2022)29USAFull-text2010–2020CirrhosisCAD30/127NA
Wang (2022)28ChinaFull-text2000–2013HCV cirrhosisCAD413/1,1542,022/6,924
MI43/1,154194/6,924
Aby (2021)37USAFull-text2019–2019CirrhosisCAD12/94NA
Afify (2021)36EgyptFull-text2020–2020HCV cirrhosisCAD7/645/61
Alshami (2021)35USAAbstract2018–2021CirrhosisCAD783/10,170360,010/20,000,530
Patel (2021)33USAFull-text2010–2017CirrhosisCAD153/682NA
Izzy (2021)34USAFull-text2008–2017CirrhosisCAD32/141NA
Srinivasamurthy (2021)32IndiaFull-textNACirrhosisCAD25/40NA
Hughes (2020)38USAFull-text2012–2017CirrhosisCAD121/231NA
Oud (2019)40USAFull-text2009–2014CirrhosisMI306/2,51114,114/51,969
Patil (2019)39IndiaFull-text2015–2017CirrhosisCAD11/177NA
Patel (2018)41USAFull-text2011–2014CirrhosisCAD84/228NA
Bhadoria (2017)43IndiaFull-text2014–2016NASH cirrhosisCAD268/1,133NA
Kazankov (2017)42DenmarkFull-text2012–2014CirrhosisCAD40/5234/52
Piazza (2016)44USAFull-text2005–2010CirrhosisCAD20/143NA
Ng (2015)45ChinaFull-text2005–2010CirrhosisCAD655/2,77986,703/755,161
An (2014)9KoreaFull-text2007–2012CirrhosisCAD399/1,0452,018/6,283
Josefsson (2014)48SwedenFull-text1999–2007CirrhosisCAD13/202NA
Kumar (2014)47USAFull-text1988–2011CirrhosisCAD55/243NA
Petit (2014)46FrenchFull-text2008–2013CirrhosisMI59/1,068NA
Gologorsky (2013)50USAFull-text2004–2006CirrhosisCAD321/11,280NA
Simons (2013)49USAAbstract2000–2011CirrhosisCAD80/324NA
Hsu (2012)53ChinaFull-text1997–2006CirrhosisACS1,218/9,7114,036/38,844
Mouchli (2012)52USAAbstract2000–2009CirrhosisCAD44/158NA
Vanwagner (2012)51USAFull-text1993–2010CirrhosisCAD34/242NA
MI10/242NA
Chen (2011)57ChinaFull-text2001–2003CirrhosisCAD138/2,336556/11,680
Chen (2011)56ChinaFull-text2004–2008CirrhosisCAD280/2,945NA
Doycheva (2011)55USAFull-text1997–2005PBCCAD14/1808/151
Patel (2011)54USAFull-text2000–2010CirrhosisCAD123/420NA
Kalaitzakis (2010)58SwedenFull-text2004–2005CirrhosisCAD26/12721/203
MI9/12710/203
Kadayifci (2008)59USAFull-text1999–2006CirrhosisCAD15/120NA
Berzigotti (2005)60ItalyFull-textNACirrhosisMI2/11815/236
Marchesini (1999)61ItalyFull-text1992–1995CirrhosisCAD11/1226/40
Ruebner (1961)62USAFull-textNACirrhosisMI13/39943/399
Howell (1960)63USAFull-text1957CirrhosisMI32/639NA
Grant (1959)64USAFull-text1953–1957CirrhosisMI24/123NA

ACS, acute coronary syndromes; CAD, coronary artery disease; HCV, hepatitis C virus; PBC, primary biliary cirrhosis; MI, myocardial infarction; NA, not available; USA, United States of America.

CAD

Based on data from the 39 studies,9,27–64 the pooled prevalence of CAD in liver cirrhosis was 18.87% (95% CI = 13.95–23.79%) (Supplementary Fig. 3A). Significant heterogeneity was observed (I2 = 99.2%, p = 0.01), and there was evidence of publication bias (p < 0.01). Meta-regression analyses suggested that publication year and CAD severity may be sources of heterogeneity (Supplementary Table 3). Subgroup analyses showed that the pooled prevalence of CAD in liver cirrhosis was 17.35% in America, 19.39% in Asia, 19.64% in Europe, and 36.30% in Africa; 13.73% in studies published before 2015 and 24.49% in studies published after 2015; 18.81% in full-text publications and 19.74% in abstracts; 19.51% in high- and moderate-quality studies and 16.87% in low-quality studies; 14.96% in studies with a sample size of ≥243 and 22.90% in those with a sample size <243; 28.79% in male patients and 16.78% in female patients; 25.69% in patients with a mean age ≥56 years and 19.15% in those with a mean age <56 years; 36.89% in patients with diabetes mellitus and 21.70% in those without; 38.17% in patients with hypertension and 21.10% in those without; 44.25% in patients with hyperlipidemia and 27.13% in those without; 28.58% in patients with a history of smoking and 20.05% in those without; and 46.96% in patients with a family history of CAD and 25.08% in those without. The prevalence of CAD by liver disease type was 21.16% in NASH cirrhosis, 15.85% in HCV cirrhosis, 17.34% in alcoholic cirrhosis, 4.04% in PBC, and 5.05% in HBV (Table 4). The prevalence of non-obstructive, obstructive, and severe CAD in liver cirrhosis was 24.44%, 13.86%, and 7.05%, respectively. Statistically significant interactions were found among subgroups by publication year, liver cirrhosis etiology, and CAD severity.

Table 4

Prevalence of CAD in liver cirrhosis: Results of meta-analyses

SubgroupNo. studiesPooled prevalence (95%CI)Heterogeneity
Pinteraction
I2 (%)p-value
Region0.88
  America2317.35% (12.42–22.27%)98.7<0.01
  Asia819.39% (10.51–28.28%)99.3<0.01
  Europe619.64% (0.00–42.01%)97.2<0.01
  Africa236.30% (0.00–86.82%)97.2<0.01
Publication year0.03
  After 20152024.49% (15.81–33.16%)99.4<0.01
  Before 20151913.73% (9.18–18.28%)98.8<0.01
Type of publication0.89
  Full-texts3618.81% (13.52–24.09%)99.2<0.01
  Abstracts319.74% (7.24–32.23%)97.5<0.01
Study quality0.69
  High and Moderate3019.51% (14.01–25.01%)99.1<0.01
  Low916.87% (5.31–28.43%)98.6<0.01
Sample size0.11
  ≥2431914.96% (9.93–19.98%)99.6<0.01
  <2432022.90% (14.49–31.31%)96.7<0.01
Sex0.33
  Male428.79% (7.57–50.02%)98.5<0.01
  Female416.78% (5.04–28.52%)93.9<0.01
Age0.39
  ≥561225.69% (13.86–37.52%)98.8<0.01
  <56819.15% (10.20–28.11%)98.9<0.01
Diabetes mellitus0.39
  Yes336.89% (11.48–62.30%)97.3<0.01
  No321.70% (0.00–45.38%)97.3<0.01
Hypertension0.37
  Yes338.17% (9.01–67.32%)98.2<0.01
  No321.10% (0.00–43.99%)96.8<0.01
Smoking history0.50
  Yes428.58% (8.61–48.55%)98.1<0.01
  No420.05% (5.35–34.76%)95.0<0.01
Family history of CAD0.36
  Yes346.96% (7.53–86.39%)94.9<0.01
  No325.08% (0.28–49.88%)98.1<0.01
Hyperlipidemia0.59
  Yes244.25% (0.00–93.36%)93.2<0.01
  No227.13% (0.00–65.30%)99.0<0.01
Etiology of cirrhosis<0.01
  HCV715.85% (7.93–25.74%)99.4<0.01
  NASH921.16% (15.71–27.15%)92.3<0.01
  Alcohol917.34% (7.73–29.66%)96.8<0.01
  PBC24.04% (0.17–12.08%)93.4<0.01
  HBV25.05% (0.67–13.06%)97.0<0.01
Severity of CAD<0.01
  Non-obstructive724.44% (14.42–36.07%)96.4<0.01
  Obstructive713.86% (8.96–19.60%)90.0<0.01
  Severe47.05% (3.03–12.46%)87.8<0.01

CAD, coronary artery disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis.

Fifteen studies compared CAD prevalence between patients with and without liver cirrhosis.9,28,31,35,36,40,42,45,53,55,57,58,60–62 The available evidence did not show a significant difference in CAD prevalence between patients with and without cirrhosis (OR = 1.29; 95% CI = 0.83–2.01; p = 0.26) (Supplementary Fig. 4A). Significant heterogeneity was present (I2 = 99.6%; p = 0.01), and publication bias was observed (p = 0.03).

ACS

Based on data from one study,53 the prevalence of ACS in liver cirrhosis was 12.54% (95% CI = 11.89–13.20%).

Only one study compared ACS prevalence between patients with and without liver cirrhosis,53 reporting a significantly higher prevalence in those with cirrhosis [12.54% (1,218/9,711) vs. 10.39% (4,036/38,844), p < 0.01].

MI

Based on data from nine studies,28,40,46,51,58,60,62–64 the pooled prevalence of MI in liver cirrhosis was 6.12% (95% CI = 3.51–9.36%) (Supplementary Fig. 3B). Significant heterogeneity was observed (I2 = 94.7%, p < 0.01), with no evidence of publication bias (p = 0.06).

Five studies compared MI prevalence between patients with and without liver cirrhosis.28,40,58,60,62 Available evidence showed no significant difference in MI prevalence between these groups (OR = 0.58; 95% CI = 0.28–1.22; p = 0.15) (Supplementary Fig. 4B). Significant heterogeneity was observed (I2 = 93.2%; p < 0.01), but there was no evidence of publication bias (p = 0.50).

Risk factors associated with CAD in cirrhosis

Risk factors for CAD occurrence

Two studies evaluated factors associated with CAD occurrence in liver cirrhosis.19,23 Meta-analyses found that diabetes mellitus (RR = 1.52; 95% CI = 1.30–1.78; p < 0.01) and hypertension (RR = 2.14; 95% CI = 1.13–4.04; p = 0.02), but not male sex, were significantly associated with CAD occurrence in liver cirrhosis (Table 5).

Table 5

Factors associated with CAD in cirrhosis

VariablesEffect size (95% CI)Heterogeneity
p-value
I2 (%)p-value
Incidence
  Sex (male)RR:0.90 (0.79–1.03)00.8620.12
  Diabetes mellitusRR:1.52 (1.30–1.78)00.755<0.01
  HypertensionRR:2.14 (1.13–4.04)78.50.0310.02
Prevalence
  AgeMD:5.68 (2.46–8.90)73.60.023<0.01
  MELD scoreMD:1.23 (−0.42–2.88)75.70.0160.14
  Child-Pugh scoreMD:0.23 (−0.24–0.71)00.6980.34
  BMIMD:−0.12 (−0.74–0.50)00.5320.70
  Sex (male)OR:2.35 (1.26–4.36)61.80.0490.01
  Diabetes mellitusOR:2.67 (1.70–4.18)27.60.251<0.01
  HypertensionOR:2.39 (1.23–4.61)610.0770.01
  History of smokingOR:1.56 (1.03–2.38)00.9310.04
  Family history of CADOR:2.18 (1.22–3.92)49.70.1370.01
  HyperlipidemiaOR:4.12 (2.09–8.13)00.522<0.01
  HCCOR:0.89 (0.64–1.23)00.9590.46
  NASH cirrhosisOR:1.59 (1.09–2.33)00.9330.02
  HCV cirrhosisOR:1.35 (1.19–1.54)00.977<0.01
  Alcoholic cirrhosisOR:1.74 (0.95–3.21)76.70.0500.07

BMI, body mass index; CAD, coronary artery disease; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease; NASH, non-alcoholic steatohepatitis.

Risk factors for CAD presence

Six studies evaluated factors associated with CAD presence in liver cirrhosis.9,27,28,36,38,58 Meta-analyses found that advanced age (MD = 5.68; 95% CI = 2.46–8.90; p < 0.01), male sex (OR = 2.35; 95% CI = 1.26–4.36; p = 0.01), diabetes mellitus (OR = 2.67; 95% CI = 1.70–4.18; p < 0.01), hypertension (OR = 2.39; 95% CI = 1.23–4.61; p = 0.01), hyperlipidemia (OR = 4.12; 95% CI = 2.09–8.13; p < 0.01), smoking history (OR = 1.56; 95% CI = 1.03–2.38; p = 0.04), family history of CAD (OR = 2.18; 95% CI = 1.22–3.92; p = 0.01), and NASH (OR = 1.59; 95% CI = 1.09–2.33; p = 0.02) and HCV (OR = 1.35; 95% CI = 1.19–1.54; p < 0.01) as etiologies of liver cirrhosis, but not alcohol abuse, hepatocellular carcinoma, BMI, or Child-Pugh or MELD scores, were significantly associated with CAD presence in liver cirrhosis (Table 5).

Discussion

Our study aimed to assess the epidemiology of CAD in patients with liver cirrhosis and evaluate the association between cirrhosis and CAD. We found that CAD is not uncommon in patients with liver cirrhosis, but current evidence does not support a definitive association between liver cirrhosis and CAD. Additionally, traditional cardiovascular risk factors, including advanced age, male sex, diabetes mellitus, hypertension, dyslipidemia, smoking, family history of CAD, and certain etiologies of chronic liver disease—namely NASH and HCV—are associated with the presence of CAD in these patients.

Our study confirms that traditional risk factors for CAD may also predict or promote the development of cardiovascular disease in patients with cirrhosis. Furthermore, liver cirrhosis is characterized by decreased nitric oxide levels, increased oxidative stress, and elevated levels of vasoconstrictor agents (such as thromboxane A2, COX-1-derived prostanoids, and endothelin-1), as well as inflammatory markers (such as tumor necrosis factor-alpha, nuclear factor kappa B, Toll-like receptor, and angiotensin II). These factors play a significant role in endothelial dysfunction, which can contribute to the development of CAD.6,65–67 In cases of infection, encephalopathy, or bleeding, a fragile hemostatic balance may be disrupted, leading to a heightened risk of thrombosis. Jepsen et al. demonstrated an 8.7-fold increased risk of MI in patients with decompensated cirrhosis who had recently undergone variceal ligation/sclerotherapy or ascites puncture/drainage within 90 days of treatment, compared to those with compensated cirrhosis.17 Additionally, decreased peripheral resistance, compensatory hyperdynamic circulation, and increased cardiac output and heart rate may reduce coronary blood flow, thereby increasing the risk of ACS.1

Patients with cirrhosis should be referred for transplantation when they develop severe hepatic dysfunction (i.e., MELD score ≥15) or experience decompensation events (i.e., ascites, variceal bleeding, hepatic encephalopathy, or hepatorenal syndrome).68 However, CAD is a significant predictor of adverse prognosis in liver transplantation candidates.13 The American Heart Association and the American College of Cardiology Foundation have recommended noninvasive stress testing for liver transplantation candidates with multiple risk factors (e.g., diabetes, prior cardiovascular disease, left ventricular hypertrophy, age over 60 years, smoking, hypertension, or dyslipidemia).69 Patients with known cardiac disease and those with abnormal screening tests should undergo further evaluation with coronary computed tomography angiography. The European Association for the Study of the Liver guidelines recommend that all liver transplant candidates undergo electrocardiography and echocardiography and that patients with multiple risk factors or those older than 50 years undergo cardiopulmonary exercise testing to identify asymptomatic CAD.70 Most guidelines focus on evaluating CAD in liver transplant candidates, with less emphasis on patients with advanced cirrhosis. High-risk cirrhotic patients should undergo a careful cardiac evaluation to promptly identify the type of CAD and stratify risk, enabling the formulation of appropriate management strategies that could reduce overall and cardiac-related mortality.

There is a mutual interaction between liver cirrhosis and CAD. Evidence suggests that CAD may be more severe in cirrhotic individuals compared to non-cirrhotic individuals.9,42 Patients with cirrhosis often exhibit significantly more non-obstructive lesions, more extensive involvement of coronary vessels,9 longer atherosclerotic plaques, and higher total volumes of calcified or non-calcified plaques.42 Additionally, increasing levels of liver fibrosis and cirrhosis biomarkers are associated with more severe plaque and CAD. Liver fibrosis (LF) scores, including the Fibrosis-4 score and the non-alcoholic fatty liver disease fibrosis score, have been shown to predict the presence of coronary calcification.71 The non-alcoholic fatty liver disease fibrosis score is positively associated with the degree of coronary stenosis, while the Fibrosis-4 score correlates with the number of diseased coronary vessels.72 LF also negatively impacts the long-term prognosis of CAD patients. A prospective cohort study indicated that higher LF scores are associated with increased risks of all-cause and cardiovascular mortality among CAD patients.73 Taken together, advanced liver fibrosis appears to correlate with the severity of CAD, suggesting that these patients may require closer monitoring and screening for cardiovascular risk factors.

Notably, the association between liver cirrhosis and CAD may depend on the underlying etiology of the cirrhosis. Our study found a positive association between HCV cirrhosis and the presence of CAD. Similarly, previous studies have shown that HCV increases the risk of CAD.74 HCV directly and indirectly influences glucose and lipid metabolism, leading to a high prevalence of insulin resistance, steatosis, and diabetes mellitus.75 Additionally, the virus may have direct effects on the vessel wall.76 Our study also found that NASH was positively associated with CAD presence in liver cirrhosis. NASH is commonly associated with dyslipidemia, insulin resistance, and increased pro-inflammatory cytokines, all of which play important roles in the pathophysiology of atherosclerosis.77 Conversely, we did not find a significant association between alcoholic cirrhosis and CAD presence; however, other studies suggest that alcoholic cirrhosis is associated with both the occurrence and severity of CAD.18,20 Furthermore, coronary arteriosclerosis is particularly extensive in alcoholic cirrhosis. Patients with alcoholic cirrhosis had significantly higher median coronary artery calcium scores, which quantify coronary artery calcification, compared to those with non-alcoholic cirrhosis.78 Alcohol-related liver disease was also significantly associated with a coronary artery calcium score >300, indicating a high risk of cardiovascular events.79 This is likely due to excessive alcohol consumption, which is associated with increased levels of low-density lipoprotein and the expression of adhesion molecules.80

A meta-analysis conducted by Zhao et al. included five studies but only pooled the prevalence of CAD in cirrhosis.10 Another meta-analysis by Ungprasert et al. included four studies and reported an increased risk of CAD in PBC patients,81 a finding not confirmed by our study. In comparison, our study has several strengths. First, to our knowledge, we are the first to systematically report the incidence of CAD, the association between CAD and liver cirrhosis, and the factors related to the occurrence and presence of CAD in cirrhosis. Second, we included all types of cirrhosis rather than focusing solely on a single type, such as PBC. Third, we performed a comprehensive literature search using three major databases without language limitations to maximize the inclusion of epidemiological studies on CAD in liver cirrhosis. Fourth, we categorized CAD into ACS and MI to explore the effects of cirrhosis on different types of CAD.

Our study also has some limitations. First, significant heterogeneity remains in our meta-analyses, which necessitates cautious interpretation of our findings. Most of the included studies were retrospective, some had small sample sizes, and they utilized various definitions and diagnostic approaches for cirrhosis and CAD, potentially introducing bias into the results. Due to substantial differences and publication bias among the included studies, the pooled results may not accurately reflect the true effect size, impacting the reliability of the results. Second, the number of relevant studies was limited, and some were of low quality, which compromised the reliability of our findings. Only five studies reported associations between specific etiologies and CAD, making our conclusions implausible. Large-scale, well-designed prospective cohort studies are necessary to support our findings in the future. Additionally, we were unable to obtain information on the use of antithrombotic drugs and antiviral drugs for HCV, which could affect CAD development. Meanwhile, we could not perform subgroup analyses according to the different stages of cirrhosis and were unable to explore the association of HBV and PBC—with significant effects on lipid metabolism—with CAD in cirrhotic patients. Third, two previous meta-analyses found significant associations between NASH and HCV with cardiovascular diseases,74,77 which appear to contradict our findings. This discrepancy may be attributed to the differences in the etiologies of cirrhosis evaluated. Our included studies featured patients with mixed etiologies of liver cirrhosis, suggesting that liver cirrhosis is related not only to NASH but also to other causes, such as HBV. Indeed, two other previous meta-analyses indicated that HBV infection does not increase the risk of CAD.82,83 Our subgroup analyses based on different etiologies of cirrhosis demonstrated that the prevalence of CAD in NASH-related cirrhosis was higher than in other etiologies. Additionally, we found that the presence of NASH in cirrhosis increased the risk of CAD by 1.59 times. Fourth, the term “primary biliary cirrhosis” has been replaced by “primary biliary cholangitis” in recent years.84 However, earlier studies specifically referred to primary biliary cirrhosis, and some patients without a definitive diagnosis of liver cirrhosis were also attributed to the primary biliary cirrhosis group, which raises the possibility of misclassification. Finally, potential competing events, such as liver-related deaths, may compromise the development of CAD during follow-up, thereby influencing the true estimates of CAD.

Conclusions

CAD is common in cirrhotic patients, but its risk may not be increased solely by the presence of liver cirrhosis. NASH and HCV do increase the risk of CAD in these patients, along with traditional cardiovascular risk factors. Large-scale prospective studies are needed to clarify how to screen for and prevent CAD in the high-risk population with liver cirrhosis.

Supporting information

Supplementary Table 1

Quality of included studies.

(DOCX)

Click here for additional data file.

Supplementary Table 2

Incidence of CAD in liver cirrhosis: Results of meta-regression analyses.

(DOCX)

Click here for additional data file.

Supplementary Table 3

Prevalence of CAD in liver cirrhosis: Results of meta-regression analyses.

(DOCX)

Click here for additional data file.

Supplementary Fig. 1

Pooled incidences of CAD (A), ACS (B), and MI (C) in liver cirrhosis.

ACS, acute coronary syndromes; CAD, coronary artery disease; MI, myocardial infarction.

(JPG)

Click here for additional data file.

Supplementary Fig. 2

Comparisons of the incidences of CAD (A) and MI (B) between patients with and without liver cirrhosis.

CAD, coronary artery disease; MI, myocardial infarction.

(JPG)

Click here for additional data file.

Supplementary Fig. 3

Pooled prevalence of CAD (A) and MI (B) in liver cirrhosis.

CAD, coronary artery disease; MI, myocardial infarction.

(JPG)

Click here for additional data file.

Supplementary Fig. 4

Comparisons of the prevalence of CAD (A) and MI (B) between patients with and without liver cirrhosis.

CAD, coronary artery disease; MI, myocardial infarction.

(JPG)

Click here for additional data file.

Declarations

Data sharing statement

Data synthesized in this meta-analysis were extracted from published studies.

Funding

The present study was partially supported by the National Key R&D Program of China (2023YFC2507500), Outstanding Youth Foundation of Liaoning Province (2022-YQ-07), and Science and Technology Plan Project of Liaoning Province (2022JH2/101500032).

Conflict of interest

XQ has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2023. The other authors have no conflict of interests related to this publication.

Authors’ contributions

Reviewed and searched the literature, collected and analyzed the data, discussed the findings, drafted the manuscript (CG), searched the literature, collected the data (LD), discussed the findings, gave critical comments (LC, ZT, FG, WA, FGR), conceived the work, reviewed the literature, interpreted the findings, and revised the manuscript (XQ). All authors contributed intellectually to the manuscript and approved the final version and publication of the manuscript.

References

  1. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398(10308):1359-1376 View Article PubMed/NCBI
  2. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 2019;234(10):16812-16823 View Article PubMed/NCBI
  3. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation 2022;145(8):e153-e639 View Article PubMed/NCBI
  4. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5(3):245-266 View Article PubMed/NCBI
  5. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43(2 Suppl 1):S121-S131 View Article PubMed/NCBI
  6. Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology 2016;64(4):1249-1264 View Article PubMed/NCBI
  7. Lu DY, Steitieh D, Feldman DN, Cheung JW, Wong SC, Halazun H, et al. Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database). Am J Cardiol 2020;125(9):1295-1304 View Article PubMed/NCBI
  8. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996;2(6):426-430 View Article PubMed/NCBI
  9. An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation 2014;130(16):1353-1362 View Article PubMed/NCBI
  10. Zhao J, Li N, Sun H, Liang C. The prevalence of coronary artery disease in patients with liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol 2018;30(1):118-120 View Article PubMed/NCBI
  11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008-2012 PubMed/NCBI
  12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535 View Article PubMed/NCBI
  13. Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, et al. A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transpl 2022;28(4):689-699 View Article PubMed/NCBI
  14. Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014;3(3):123-128 View Article PubMed/NCBI
  15. Huang X, Abougergi MS, Sun C, Murphy D, Sondhi V, Chen B, et al. Incidence and outcomes of thromboembolic and bleeding events in patients with liver cirrhosis in the USA. Liver Int 2023;43(2):434-441 View Article PubMed/NCBI
  16. Abdul-Rahman K, Schneider H, Becker H, Wedemeyer H, Maasoumy B, Stahmeyer JT. Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study. J Hepatol 2022;77:S83 View Article
  17. Jepsen P, Tapper EB, Deleuran T, Kazankov K, Askgaard G, Sørensen HT, et al. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology 2021;74(5):2725-2734 View Article PubMed/NCBI
  18. Deleuran T, Schmidt M, Vilstrup H, Jepsen P. Time-dependent incidence and risk for myocardial infarction in patients with alcoholic cirrhosis. Eur J Clin Invest 2020;50(4):e13205 View Article PubMed/NCBI
  19. Tsai MC, Yang TW, Wang CC, Wang YT, Sung WW, Tseng MH, et al. Favorable clinical outcome of nonalcoholic liver cirrhosis patients with coronary artery disease: A population-based study. World J Gastroenterol 2018;24(31):3547-3555 View Article PubMed/NCBI
  20. Lin SY, Lin CL, Lin CC, Wang IK, Hsu WH, Kao CH. Risk of acute coronary syndrome and peripheral arterial disease in chronic liver disease and cirrhosis: A nationwide population-based study. Atherosclerosis 2018;270:154-159 View Article PubMed/NCBI
  21. Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, et al. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J 2018;198:4-17 View Article PubMed/NCBI
  22. Serper M, Taddei TH, Kaplan DE. Prevalence and factors associated with cardiovascular events and mortality among 21,984 veterans with cirrhosis. Hepatology 2017;22(Suppl 1):1110-1A
  23. Wang C, Zhao P, Liu W. Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med 2014;7(9):2921-2924 PubMed/NCBI
  24. Pavel O, Ardevol A, Graupera I, Colomo A, Concepción M, Hernandez-Gea V, et al. Influence of cardiac and respiratory complications on the outcome of acute gastrointestinal bleeding in cirrhosis: 1163. Hepatology 2012;56:750A
  25. Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008;103(11):2784-2788 View Article PubMed/NCBI
  26. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51(2):265-269 View Article PubMed/NCBI
  27. Reznicek E, Sasaki K, Montane B, Sims A, Beard J, Fares M, et al. Outcomes of Liver Transplantation in Patients With Preexisting Coronary Artery Disease. Transplantation 2023;107(4):933-940 View Article PubMed/NCBI
  28. Wang CH, Ou SF, Tseng YT. Long-term impact of certain coexisting extrahepatic unisystem and multisystem manifestations on trends in incidence of liver cirrhosis in treatment-naïve patients with chronic hepatitis C: A nested case-control study. Medicine (Baltimore) 2022;101(29):e29697 View Article PubMed/NCBI
  29. Pelayo J, Lo KB, Sultan S, Quintero E, Peterson E, Salacupa G, et al. Invasive hemodynamic parameters in patients with hepatorenal syndrome. Int J Cardiol Heart Vasc 2022;42:101094 View Article PubMed/NCBI
  30. Berry K, Duarte-Rojo A, Grab JD, Dunn MA, Boyarsky BJ, Verna EC, et al. Cognitive Impairment and Physical Frailty in Patients With Cirrhosis. Hepatol Commun 2022;6(1):237-246 View Article PubMed/NCBI
  31. Abureesh M, Alkhayyat M, Abualnadi I, Badran R, Henneberry JD, Sadiq W, et al. Epidemiology of Depressive Disorders in Patients With Liver Cirrhosis: A Population-Based Study in the United States. Prim Care Companion CNS Disord 2022;24(1):20m02889 View Article PubMed/NCBI
  32. Srinivasamurthy BC, Saravanan SP, Marak FK, Manivel P, Bhat RV, Mathiyazhagan D. Morphological Cardiac Alterations in Liver Cirrhosis: An Autopsy Study. Heart Views 2021;22(2):96-101 View Article PubMed/NCBI
  33. Patel S, Siddiqui MB, Chandrakumaran A, Rodriguez VA, Faridnia M, Hernandez Roman J, et al. Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. Dig Dis Sci 2021;66(1):263-272 View Article PubMed/NCBI
  34. Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, et al. Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria. Liver Transpl 2021;27(6):876-886 View Article PubMed/NCBI
  35. Alshami M, Badran R, Abouyassine A, Dahabra L. The prevalence of coronary artery diseases in patients with liver cirrhosis. Am J Gastroenterol 2021;116(SUPPL):S574 View Article
  36. Afify S, Eysa B, Hamid FA, Abo-Elazm OM, Edris MA, Maher R, et al. Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study. World J Gastroenterol 2021;27(42):7362-7375 View Article PubMed/NCBI
  37. Aby ES, Pham NV, Yum JJ, Dong TS, Ghasham H, Bedier F, et al. Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis. Dig Dis Sci 2021;66(10):3343-3351 View Article PubMed/NCBI
  38. Hughes DL, Rice JD, Burton JR, Jin Y, Peterson RA, Ambardekar AV, et al. Presence of any degree of coronary artery disease among liver transplant candidates is associated with increased rate of post-transplant major adverse cardiac events. Clin Transplant 2020;34(11):e14077 View Article PubMed/NCBI
  39. Patil V, Jain M, Venkataraman J. Paracentesis-induced acute kidney injury in decompensated cirrhosis - prevalence and predictors. Clin Exp Hepatol 2019;5(1):55-59 View Article PubMed/NCBI
  40. Oud L. In-hospital cardiopulmonary resuscitation of patients with cirrhosis: A population-based analysis. PLoS One 2019;14(9):e0222873 View Article PubMed/NCBI
  41. Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl 2018;24(3):333-342 View Article PubMed/NCBI
  42. Kazankov K, Munk K, Øvrehus KA, Jensen JM, Siggaard CB, Grønbaek H, et al. High burden of coronary atherosclerosis in patients with cirrhosis. Eur J Clin Invest 2017;47(8):565-573 View Article PubMed/NCBI
  43. Bhadoria AS, Kedarisetty CK, Bihari C, Kumar G, Jindal A, Bhardwaj A, et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. Liver Int 2017;37(9):1397-1404 View Article PubMed/NCBI
  44. Piazza NA, Singal AK. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis. Exp Clin Transplant 2016;14(1):79-85 View Article PubMed/NCBI
  45. Ng KJ, Lee YK, Huang MY, Hsu CY, Su YC. Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan. J Thromb Haemost 2015;13(2):206-213 View Article PubMed/NCBI
  46. Petit JM, Hamza S, Rollot F, Sigonney V, Crevisy E, Duvillard L, et al. Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis. Acta Diabetol 2014;51(3):455-60 View Article PubMed/NCBI
  47. Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci 2014;59(8):1958-1965 View Article PubMed/NCBI
  48. Josefsson A, Fu M, Björnsson E, Castedal M, Kalaitzakis E. Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis. Transplantation 2014;98(1):107-114 View Article PubMed/NCBI
  49. Simons S, Forde KA, Li YR, Reddy KR, Bahirwani R. Cardiovascular disease in liver transplant candidates with NASH/cryptogenic cirrhosis. Gastroenterology 2013;144(5):S1013 View Article
  50. Gologorsky E, Pretto EA, Fukazawa K. Coronary artery disease and its risk factors in patients presenting for liver transplantation. J Clin Anesth 2013;25(8):618-623 View Article PubMed/NCBI
  51. Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012;56(5):1741-1750 View Article PubMed/NCBI
  52. Mouchli M, El Chafic AH, Liangpunsakul S. Echocardiographic characteristics in liver cirrhosis according to meld score and the effect of liver transplant. Am J Gastroenterol 2012;107:S199 View Article
  53. Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Hepatology 2012;56(2):698-705 View Article PubMed/NCBI
  54. Patel S, Kiefer TL, Ahmed A, Ali ZA, Tremmel JA, Lee DP, et al. Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. Am J Cardiol 2011;108(11):1552-1555 View Article PubMed/NCBI
  55. Doycheva I, Chen C, Pan JJ, Levy C. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol 2011;3(4):93-98 View Article PubMed/NCBI
  56. Chen YW, Chen HH, Wang TE, Chang CW, Chang CW, Chen WC, et al. The dissociation between the diabetes and both Child-Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic. Hepatol Int 2011;5(4):955-964 View Article PubMed/NCBI
  57. Chen YH, Chen KY, Lin HC. Non-alcoholic cirrhosis and the risk of stroke: a 5-year follow-up study. Liver Int 2011;31(3):354-360 View Article PubMed/NCBI
  58. Kalaitzakis E, Rosengren A, Skommevik T, Björnsson E. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci 2010;55(2):467-475 View Article PubMed/NCBI
  59. Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol 2008;49(4):595-599 View Article PubMed/NCBI
  60. Berzigotti A, Bonfiglioli A, Muscari A, Bianchi G, Libassi S, Bernardi M, et al. Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int 2005;25(2):331-336 View Article PubMed/NCBI
  61. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, et al. Cardiovascular disease in cirrhosis—a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999;94(3):655-662 View Article PubMed/NCBI
  62. RUEBNER BH, MIYAI K, ABBEY H. The low incidence of myocardial infarction in hepatic cirrhosis. A statistical artefact?. Lancet 1961;2(7218):1435-1436 View Article PubMed/NCBI
  63. HOWELL WL, MANION WC. The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: A review of 639 cases of cirrhosis of the liver from 17,731 autopsies. Am Heart J 1960;60:341-344 View Article PubMed/NCBI
  64. GRANT WC, WASSERMAN F, RODENSKY PL, THOMSON RV. The incidence of myocardial infarction in portal cirrhosis. Ann Intern Med 1959;51:774-779 View Article PubMed/NCBI
  65. Wever RM, Lüscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998;97(1):108-112 View Article PubMed/NCBI
  66. Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M. Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim Pol 2011;58(1):59-65 PubMed/NCBI
  67. Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol 2015;7(3):443-459 View Article PubMed/NCBI
  68. Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol 2023;21(8):2150-2166 View Article PubMed/NCBI
  69. Cheng XS, VanWagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP, et al. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation 2022;146(21):e299-e324 View Article PubMed/NCBI
  70. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016;64(2):433-485 View Article PubMed/NCBI
  71. Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int 2021;15(2):413-423 View Article PubMed/NCBI
  72. Yan Z, Liu Y, Li W, Zhao X, Lin W, Zhang J, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. Eur J Clin Invest 2022;52(11):e13855 View Article PubMed/NCBI
  73. Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 2020;299:45-52 View Article PubMed/NCBI
  74. Wen D, Du X, Dong JZ, Ma CS. Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis. Eur J Intern Med 2019;63:69-73 View Article PubMed/NCBI
  75. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015;30(5):879-884 View Article PubMed/NCBI
  76. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014;61(1 Suppl):S69-S78 View Article PubMed/NCBI
  77. Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, et al. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2022;20(11):2462-2473.e10 View Article PubMed/NCBI
  78. Danielsen KV, Wiese S, Hove J, Bendtsen F, Møller S. Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?. Dig Dis Sci 2018;63(5):1355-1362 View Article PubMed/NCBI
  79. Benrajab K, Godman M, Emhmed Ali S, Sorrell V, Salama F, Shah M, et al. Alcohol-related cirrhosis is associated with high coronary artery calcium scores in patients undergoing evaluation for orthotopic liver transplantation. Clin Transplant 2021;35(5):e14282 View Article PubMed/NCBI
  80. Carnevale R, Nocella C. Alcohol and cardiovascular disease: still unresolved underlying mechanisms. Vascul Pharmacol 2012;57(2-4):69-71 View Article PubMed/NCBI
  81. Ungprasert P, Wijarnpreecha K, Ahuja W, Spanuchart I, Thongprayoon C. Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies. Hepatol Res 2015;45(11):1055-1061 View Article PubMed/NCBI
  82. Wang Y, Xiong J, Niu M, Xu W, Xu K, Zhong H. Hepatitis B virus and the risk of coronary heart disease: A comprehensive systematic review and meta-analyses of observational studies. Int J Cardiol 2018;265:204-209 View Article PubMed/NCBI
  83. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Hepatitis B virus infection and risk of coronary artery disease: a meta-analysis. Ann Transl Med 2016;4(21):423 View Article PubMed/NCBI
  84. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Gastroenterology 2015;149(6):1627-1629 View Article PubMed/NCBI
Copyright © 2024 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Journal of Clinical and Translational Hepatology
  • pISSN 2225-0719
  • eISSN 2310-8819

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2635623
  • Visits today : 1616
Back to Top

Risk of Coronary Artery Disease in Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis

Chunru Gu, Liyan Dong, Lu Chai, Zhenhua Tong, Fangbo Gao, Walter Ageno, 
Fernando Gomes Romeiro, Xingshun Qi
  • Reset Zoom
  • Download TIFF